These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 15995960)
1. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. Brumme ZL; Goodrich J; Mayer HB; Brumme CJ; Henrick BM; Wynhoven B; Asselin JJ; Cheung PK; Hogg RS; Montaner JS; Harrigan PR J Infect Dis; 2005 Aug; 192(3):466-74. PubMed ID: 15995960 [TBL] [Abstract][Full Text] [Related]
2. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181 [TBL] [Abstract][Full Text] [Related]
3. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065 [TBL] [Abstract][Full Text] [Related]
4. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499 [TBL] [Abstract][Full Text] [Related]
5. Co-receptor switch during HAART is independent of virological success. Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy. Brumme ZL; Chan KJ; Dong WW; Wynhoven B; Mo T; Hogg RS; Montaner JS; O'Shaughnessy MV; Harrigan PR Antivir Ther; 2003 Apr; 8(2):91-6. PubMed ID: 12741620 [TBL] [Abstract][Full Text] [Related]
7. CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. Low AJ; Marchant D; Brumme CJ; Brumme ZL; Dong W; Sing T; Hogg RS; Montaner JS; Gill V; Cheung PK; Harrigan PR AIDS Res Hum Retroviruses; 2008 Feb; 24(2):219-28. PubMed ID: 18240966 [TBL] [Abstract][Full Text] [Related]
16. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700 [TBL] [Abstract][Full Text] [Related]
17. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. Karlsson I; Antonsson L; Shi Y; Karlsson A; Albert J; Leitner T; Olde B; Owman C; Fenyö EM AIDS; 2003 Dec; 17(18):2561-9. PubMed ID: 14685050 [TBL] [Abstract][Full Text] [Related]
18. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion. Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848 [TBL] [Abstract][Full Text] [Related]
19. [Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability]. Hei FX; Hong KX; Song YH; Tang HL; Peng H; Xu JQ; Xing H; Shao YM Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1968-72. PubMed ID: 15730807 [TBL] [Abstract][Full Text] [Related]